Drugs / NP202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02557217 | Oct 2015 → Dec 2017 | ST-elevation myocardial infarction | Armaron Bio Pty Ltd | Unknown | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02557217 ↗ |
| Action | Inhibit | “NP202, an orally active inhibitor of CaMKIId” PMID 33851966 ↗ Jul 2021 |
| Route | Oral | “1000mg oral NP202 daily for 90 days” NCT02557217 ↗ |
| Target | CAMK2D | “NP202, an orally active inhibitor of CaMKIId” PMID 33851966 ↗ Jul 2021 |